In This Section

Program

Please note that this meeting will take place as an in-person event in Denver and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

FRIDAY, SEPTEMBER 19

SATURDAY, SEPTEMBER 20

SUNDAY, SEPTEMBER 21

Friday, September 19

REGISTRATION

3-5 p.m. | Colorado Ballroom Foyer

WELCOME AND OPENING Keynote

5-5:05 p.m. | Colorado Ballroom

  • Ronald Buckanovich, Magee-Womens Research Institute, Pittsburgh, Pennsylvania
  • Jung-Min Lee, National Cancer Institute, Bethesda, Maryland
  • Elizabeth M. Swisher, University of Washington, Seattle, Washington
  • Oladapo Yeku, Massachusetts General Hospital, Boston, Massachusetts

Introduction by the Ovarian Cancer Research Alliance (OCRA)

5:05-5:10 p.m. | Colorado Ballroom

  • Audra Moran, President & CEO, Ovarian Cancer Research Alliance

Opening Keynote Address

5:10-5:50 p.m. | Colorado Ballroom

  • Keynote Introduction
    Ronald Buckanovich, Magee-Womens Research Institute, Pittsburgh, Pennsylvania
  • Building the foundations for effective immunotherapy of ovarian cancer
    George Coukos, Ludwig Institute for Cancer Research, Switzerland

Patient advocacy: Clinical trials and survivorship

5:50-7 p.m. | Colorado Ballroom

Session Chair: Goli Samimi, National Cancer Institute, Bethesda, Maryland

  • 5:50 p.m. | Full circle: Return of value to ovarian cancer research participants, advocates, and survivors
    Celeste Leigh Pearce, University of Michigan School of Public Health, Ann Arbor, Michigan
  • 6:05 p.m. | Prevention of taxane-induced peripheral neuropathy
    Kathryn Pennington, Alaska Women’s Cancer Care, Anchorage, Alaska
  • 6:20 p.m. | TEAL: Trial of Exercise And Lifestyle in Women with Ovarian Cancer – Improving treatment tolerance through lifestyle medicine
    Tracy E. Crane, University of Miami Miller School of Medicine, Miami, Florida
  • 6:35 p.m. | The biology of stress and resilience in ovarian cancer
    Susan K. Lutgendorf, University of Iowa, Iowa City, Iowa
  • 6:50 p.m. | Survival divide: A comparative analysis of black women and white women with ovarian cancer in the United States*              
    Alexandria Fletcher, H. Lee Moffit Cancer Center, Tampa, Florida

Lightning Talks I

7-7:30 p.m. | Colorado Ballroom

Session Chair: Oladapo Yeku, Massachusetts General Hospital, Boston, Massachusetts

  • 7:02 p.m. | A PARP-inhibitor-induced early adaptive survival response is tackled through depletion of FRA1 by Brigatinib in high-grade serous ovarian carcinoma
    Julie Duffield, Mayo Clinic, Rochester, Minnesota
  • 7:05 p.m. | miR-195 Re-expression reverses chemoresistance in ovarian cancer by suppressing WNT7A/β-Catenin signaling
  • Shailendra Dwivedi, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma
  • 7:08 p.m. | PARP-targeted alpha therapy for the treatment of PARP inhibitor resistant ovarian cancer
    Sarah Gitto, University of Pennsylvania, Philadelphia, Pennsylvania
  • 7:11 p.m. | PAX8-dependent signaling networks as drivers of progression and immune evasion in high grade serous ovarian cancer
    Joohyun Im, University of Illinois Chicago, Chicago, Illinois
  • 7:14 p.m. | Monitoring PARP trapping in live ovarian cancer cells using a CRISPR-engineered FRET biosensor
    Daniel J. Marks, Imperial College, London, United Kingdom
  • 7:17 p.m. | Targeting a cancer-specific mitotic vulnerability in ovarian cancer by combining Mirvetuximab Soravtansine with inhibitors of Polo-like kinase 1
    Jesse Patterson, Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts
  • 7:20 p.m. | Preclinical evaluation of PTT, an At-211-labeled Rucaparib analogue, as a theranostic Agent for cancer therapy
    Aladdin Riad, University of Pennsylvania, Philadelphia, Pennsylvania
  • 7:24 p.m. | Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005)
    Isabel Rodriquez, University of Washington, Seattle, Washington
  • 7:27 p.m. | Targeting translesion synthesis to enhance PARP inhibitor efficacy and prevent resistance in BRCA-deficient ovarian cancer
    Qi-En Wang, The Ohio State University, Columbus, Ohio

Opening Reception and Poster Session A

7:30–9 p.m. | Aspen Ballroom

Saturday, September 20

Continental Breakfast

7-8 a.m. | Colorado Ballroom Foyer/Maroon Peak

Plenary Session 1: Tumor initiation

8-9:50 a.m. | Colorado Ballroom

Session Chair: Charles Ishak, University of Texas MD Anderson Cancer Center, Houston, Texas

  • 8:00 a.m. | Soil forming the seed: stromal drivers of ovarian cancer initiation
    Lan G. Coffman, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
  • 8:25 a.m. | Discovery of fitness fingerprints and flower monoclonal antibody therapy in ovarian cancer
    Rajan Gogna, Virginia Commonwealth University, Richmond, Virginia
  • 8:50 a.m. | Spatially resolved epithelial and immune heterogeneity reveals distinct endometriosis-related precursors to ovarian cancer*
    Valentina Iacobelli, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
  • 9:00 a.m. | Immune suppression in the fallopian tube: Insights from the pre-cancer atlas
    Tanjina Kader, Harvard Medical School, Boston, Massachusetts
  • 9:25 a.m. | Understanding the cellular origins of ovarian cancer histotypes
    Hui Shen, Van Andel Institute, Grand Rapids, Michigan

Break

9:50-10:10 a.m. | Colorado Ballroom Foyer

Proffered Talks

10:10-11:20 a.m. | Colorado Ballroom

Session Chair: Jung-Min Lee, National Cancer Institute, Bethesda, Maryland

  • 10:10 a.m. | Gene-modified iPS-derived MSC restore a ‘Hot’ immune microenvironment in high-grade serous ovarian cancer
    Michael Andreeff, University of Texas MD Anderson Cancer Center, Houston, Texas
  • 10:20 a.m. | Enhancing anti-tumor immunity through targeting DDR2 on cancer-associated fibroblasts in ovarian cancer
    Jaidev Bapat, University of California San Francisco, San Francisco, California
  • 10:30 a.m. | Organoid models reveal distinct mechanisms of pre-tumor immune surveillance in high grade serous ovarian cancer
    Jianmei Hou, NYU Grossman SOM, New York, New York
  •  10:40 a.m. | Phase 2 study of the PD-L1 inhibitor durvalumab and VEGFR inhibitor Cediranib combination with and without PARP inhibitor Olaparib in patients with recurrent ovarian cancer
    Junya Tabata, National Cancer Institute, Bethesda, Maryland
  • 10:50 a.m. | Exploiting CTPS1 dependency for the treatment of ovarian cancer
    Xiyin Wang, Mayo Clinic, Rochester, Minnesota
  • 11:00 a.m. | Metabolic reprogramming of ovarian CD137+ TILs for treatment
    Stephanie Mills, Medical University of South Carolina, Charleston, South Carolina
  • 11:10 a.m. | IL1β+ myeloid cells fuel/induce neutrophil-driven chemoresistance in metastatic ovarian cancer
    Nan Zhang, The Wistar Institute, Philadelphia, Pennsylvania

Plenary Session 2: Tumor heterogeneity

11:20 a.m.- 12:55 p.m. | Colorado Ballroom

Session Chair: Shailendra Dwivedi, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma

  • 11:20 a.m. | Leveraging ovarian cancer heterogeneity to drive precision therapeutic innovation
    Rugang Zhang, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 11:45 a.m. | Single cell multiomic analysis of high-grade serous ovarian carcinoma reveals an intrinsic epigenetic program that primes chemotherapy tolerance in persister cells*
    Mihai Dumbrava, Mayo Clinic Alix School of Medicine, Rochester, Minnesota
  • 11:55 a.m. | Mechanisms and consequences of bispecific T-cell engager immunotherapy for ovarian cancer           
    Oladapo Yeku, Massachusetts General Hospital, Boston, Massachusetts
  • 12:15 p.m. | CRISPRi screening reveals RNA editing and the integrated stress response as major determinants of platinum and taxol sensitivity in high-grade serous ovarian cancer*
    Yi Wen Kong, Massachusetts Institute of Technology, Cambridge, Massachusetts
  • 12:25 p.m. | Targeting quiescent cancer cells to overcome chemotherapy resistance
    Ronald Buckanovich, Magee-Womens Research Institute, Pittsburgh, Pennsylvania

Short talks selected from proffered abstracts

Lunch on own

1- 2:30 p.m.

Plenary Session 3: Tumor immunology (biology)

2:30–4:05 p.m. | Colorado Ballroom

Session Chair: Saranya Rajendran, Indiana University School of Medicine, Indianapolis, Indiana

  • 2:30 p.m. | Reprogramming tumor-associated myeloid cells to improve ovarian cancer therapies 
    Sandra Cascio, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 2:55 p.m. | Enhancing T cell metabolic fitness for ovarian cancer immunotherapy
    Juan Cubillos-Ruiz, Weill Cornell Medicine, New York, New York
  • 3:20 p.m. | Lipid-droplet associated hydrolase (LDAH) dysregulates lipid metabolism and polarization of TAMs in ovarian cancer*
    Bhawna Deswal, Albany Medical College, Albany, New York
  • 3:30 p.m. | Enhancing adoptive T cell efficacy by elucidating and counteracting inhibitory factors in the tumor microenvironment
    Daniel Powell Jr., University of Pennsylvania, Philadelphia, Pennsylvania
  • 3:55 p.m. | Chronic stress drives ovarian cancer progression via myeloid-derived suppressor cells infiltration and notch signaling pathway activation*
    Yadiel Rivera-Lopez, Ponce Health Sciences University, Ponce, Puerto Rico 

Short talks selected from proffered abstracts

BReak

4:05– 4:25 p.m. | Colorado Ballroom Foyer

Plenary Session 4: Precision therapy

4:05-6 p.m. | Colorado Ballroom

Session Chair: Rebecca Porter, Rebecca Porter, Dana-Farber Cancer Institute, Boston, Massachusetts and Melica Brodeur, McGill University, Montreal, Quebec, Canada

  • 4:25 p.m. | Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer
    Mary Margaret Mullen, Washington University School of Medicine, St. Louis, Missouri
  • 4:50 p.m. | Targeting chronic inflammation in ovarian cancer through immune engineering*
    Zeda Zhang, Memorial Sloan Kettering Cancer Center, New York, New York
  • 5:00 p.m. | Advancing precision therapy through molecular profiling and targeting DNA replication vulnerabilities in ovarian cancer
    Jung-Min Lee, National Cancer Institute, Bethesda, Maryland
  • 5:25 p.m. | Targeting RAS-MAPK signaling pathway in low grade serous ovarian carcinoma
    Susana Banerjee, The Royal Marsden Hospital, London, United Kingdom
  • 5:50 p.m. | Targeting KRAS mutation to overcome immunotherapy resistance in ARID1A-mutated ovarian cancer*
    Ayumu Matsuoka, University of Texas MD Anderson Cancer Center, Houston, Texas

Lightning Talks II

6-6:35 p.m. | Colorado Ballroom

Session Chair: Ronald Bukanovich, Magee-Womens Research Institute, Pittsburgh, Pennsylvania

  • 6:02 p.m. | Evaluating spatial inter-tumor heterogeneity in whole genome duplication states and homologous recombination deficiency status in advanced ovarian high grade serous carcinoma
    Paula Cunnea, Imperial College London, London, United Kingdom
  • 6:05 p.m. | Discerning mechanisms of semaphorin 7A-mediated therapy resistance and tumor progression in high-grade serous carcinoma of tubo-ovarian origin
    Alan Elder, University of Colorado Anschutz Medical Campus, Aurora, Colorado
  • 6:08 p.m. | BRCA1 regulates ZNFX1-induced mitochondrial dysfunction and STING activation in high grade serous ovarian cancer
    Zahra Gohari, University of Maryland, Baltimore, Maryland
  •  6:11 p.m. | Serum-based multi-omic signatures of ovarian cancer in women with vague abdominal symptoms: analysis of two independent cohorts
     Abigail McElhinny, AOA Dx, Denver, Colorado
  • 6:14 p.m. | Chronic stress-induced hippocampal changes in murine ovarian cancer models: a link to depressive-like behaviors
    Luinet Melendez, Ponce Health Sciences University, Ponce, Puerto Rico
  • 6:17 p.m. | Ascites-derived natural killer (NK) cells exhibit chronic overstimulation and metabolic dysfunction in patients with advanced epithelial ovarian cancer
    Rebecca Porter, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 6:20 p.m. | Loss of SMARCA4 leads to intron retention and generation of tumor-associated antigens in small cell carcinoma of the ovary, hypercalcemic type
    Elizabeth Raupach, Mayo Clinic, Scottsdale, Arizona
  • 6:23 p.m. | Investigating the interplay between BRCA status and WT1-CD200 axis in stromal regulation of TLS formation in HGSOC
    Swati Suresh, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 6:26 p.m. | Homologous recombination DNA repair dependent survival associations in high-grade serous ovarian carcinoma: an ovarian tumor tissue analysis consortium study
    Ashley Weir, The Walter and Eliza Hall Institute, Parkville, Australia
  • 6:29 p.m. | Dual roles of LATS1/2 in ovarian cancer reveal critical context dependence of hippo pathway signaling
    Yalun Zhu, University of Ottawa, Ottawa, Canada
  • 6:32 p.m. | Complement C3 inhibition as a novel immunotherapy strategy in recurrent ovarian cancer with malignant effusions: Interim results from a phase 2 trial of Pegcetacoplan
    Emise Zsiros, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Reception and Poster Session B

6:35-8:05 p.m. | Aspen Ballroom

Sunday, September 21

Continental Breakfast

7-8 a.m. | Colorado Ballroom Foyer/Maroon Peak

Plenary Session 5: Tumor immunology

8-9:25 a.m. | Colorado Ballroom

Session Chair: Lindsay Brubaker, University of Colorado, Denver, Colorado and Rita Serda, University of New Mexico, Albuquerque, New Mexico

  • 8:00 a.m. | Cracking the code: Identifying immunogenic targets in ovarian tumors
    Marion R. Curtis, Mayo Clinic, Phoenix, Arizona
  • 8:25 a.m. | ARID4B induces immune escape in high-grade serous ovarian cancer by upregulating B3GNT5-mediated glycosphingolipid synthesis*
    Yiming Fang, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 8:35 a.m. | Dendritic cells and modulation of TME in the therapy of ovarian cancer
    Pawel Kalinski, Roswell Park Comprehensive Cancer Center, Buffalo, New York
  • 9:00 a.m. | Treatment of advanced ovarian cancer using CAR-NK cellsBranden S. Moriarity, University of Minnesota, Minneapolis, Minnesota
  • 9:25 a.m. | Tumor-derived IL-4 links chemotherapy to immunotherapy resistance in ovarian cancer*
  • Alessia Baccarini, Icahn School of Medicine at Mount Sinai, New York, New York

Break

9:35-9:55 a.m. | Colorado Ballroom Foyer

Plenary Session 6: Genomics

9:55-11:30 a.m. | Colorado Ballroom

Session Chair: Isra Elhussin, Tuskegee University, Tuskegee, Alabama

  • 9:55 a.m. | BRCA mutations and protein products in cancer
    Neil Johnson, Fox Chase Cancer Center, Philadelphia, Pennsylvania
  • 10:20 a.m. | Characterizing resistance at single cell resolution in HR deficient HGSOC*
    Elizabeth Christie, Peter MacCallum Cancer Centre, Victoria, Australia
  • 10:30 a.m. | Clonal hematopoiesis and risk of therapy-related myeloid neoplasms in tubo-ovarian cancer survivors
    Elizabeth M. Swisher, University of Washington, Seattle, Washington
  • 10:55 a.m. | Mutational signatures in ovarian cancer
    Kalyan Banda, Fred Hutchinson Cancer Center, Seattle, Washington
  • 11:20 a.m. | Ultra-deep characterization of TP53 somatic evolution in the fallopian tube and its association with ovarian cancer risk*
  • Coohleen Ann Coombes, University of Washington, Seattle, Washington

Short talk selected from proffered abstracts

Break

11:30-11:45 a.m. | Colorado Ballroom Foyer

Keynote 2

11:45 a.m.-12:20 p.m. | Colorado Ballroom

  • Keynote Introduction
    Elizabeth M. Swisher, University of Washington, Seattle, Washington
  • Frontiers of tumor evolution in ovarian cancer
    Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York

Plenary Session 7: Pathology

12:10-1:35 p.m. | Colorado Ballroom

Session Chair: Rinda Soong, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

  • 12:20 p.m. | AI-powered discovery of digital biomarkers in ovarian cancer
    Heba Sailem, King’s College London, London, United Kingdom
  • 12:45 p.m. | International multicentrer validation and clinical implementation of AI-driven support for ultrasound detection of ovarian cancer
    Elisabeth Epstein, Karolinska Institute, Stockholm, Sweden
  • 1:10 p.m. | Early detection of ovarian cancer using cell-free DNA fragmentomes
    Jillian A. Phallen, Johns Hopkins University, Baltimore, Maryland

Closing Remarks and Departure

1:35 p.m. | Colorado Ballroom